Back

Veillonella parvula: a strictly anaerobic bacterium with high efficacy for safe and specific tumor targeting and colonization

Kefayat, A.; Ghahremani, F.; Rostami, S.

2021-05-11 cancer biology
10.1101/2021.05.10.443531 bioRxiv
Show abstract

Bacterial cancer therapy has gained lots of attention in the past decade and is now considering a reliable option for the future. However, some concerns have limited its application into clinic settings like insufficient colonization of tumors and infectious origin of the currently used bacteria like Clostridium and Salmonella species, especially in cancer patients which exhibit different levels of immunocompromising. In the present study, Veillonella parvula (V. parvula) as a strictly anaerobic bacterium which has rarely identified as a pathogen in human, was administrated into 4T1 breast tumor-bearing mice. At first, 4T1 breast tumor-bearing BALB/c mice were injected with 107 bacteria intravenously, intraperitoneally, orally, or intratumorally. The best administration route according to tumor colonization and safety was selected. Then, the therapeutic effect of V. parvula administration was investigated according to the 4T1 breast tumors growth, metastasis, and tumor-bearing mice survival. Besides, histopathological evaluations were done to estimate microscopic changes at the inner of the tumor. V. parvula exhibited significant tumor-targeting and colonization efficacy, 24 h after intravenous administration and formed clustered colonies at the central region of the tumors. Although a negligible number of the bacteria were localized at normal organs, these organs became clear from the bacteria after 72 h, and no side effects or death were observed at the animals after intravenous administration of V. parvula. Although mean tumor volumes in the V. parvula treated group was lower than the control (~ 25.4%), their difference wasnt statistically significant (P > 0.05). Despite significant tumor colonization (5500000:1 in comparison with normal organs after 72 h), V. parvula didnt cause a significant therapeutic effect on the metastasis or survival time of tumor-bearing mice. Taking together, V. parvula is a completely safe and tumor-specific agent per se, without any genetic manipulation. Also, it exhibits high tumor penetration and colonization at the deep regions of the tumor.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 10%
17.6%
2
Pathogens
53 papers in training set
Top 0.1%
10.2%
3
Scientific Reports
3102 papers in training set
Top 9%
8.5%
4
Antibiotics
32 papers in training set
Top 0.2%
6.9%
5
Frontiers in Oncology
95 papers in training set
Top 0.8%
4.3%
6
Microbiology Spectrum
435 papers in training set
Top 0.7%
3.7%
50% of probability mass above
7
BMC Microbiology
35 papers in training set
Top 0.1%
3.7%
8
PeerJ
261 papers in training set
Top 3%
2.9%
9
Microorganisms
101 papers in training set
Top 0.4%
2.1%
10
BioMed Research International
25 papers in training set
Top 1%
2.1%
11
International Journal of Molecular Sciences
453 papers in training set
Top 6%
1.9%
12
RSC Advances
18 papers in training set
Top 0.4%
1.9%
13
Frontiers in Microbiology
375 papers in training set
Top 5%
1.8%
14
International Journal of Biological Macromolecules
65 papers in training set
Top 2%
1.7%
15
F1000Research
79 papers in training set
Top 2%
1.7%
16
Heliyon
146 papers in training set
Top 2%
1.5%
17
BMC Cancer
52 papers in training set
Top 2%
1.3%
18
mSphere
281 papers in training set
Top 4%
1.2%
19
Journal of Medical Virology
137 papers in training set
Top 4%
0.8%
20
Life Sciences
25 papers in training set
Top 2%
0.7%
21
Database
51 papers in training set
Top 1%
0.7%
22
Molecules
37 papers in training set
Top 2%
0.7%
23
Pharmaceuticals
33 papers in training set
Top 2%
0.7%
24
Royal Society Open Science
193 papers in training set
Top 5%
0.7%
25
Archives of Clinical and Biomedical Research
28 papers in training set
Top 3%
0.6%
26
Aging
69 papers in training set
Top 3%
0.6%
27
Environmental Research
46 papers in training set
Top 2%
0.6%
28
Biomedicines
66 papers in training set
Top 4%
0.6%
29
ACS Infectious Diseases
74 papers in training set
Top 1%
0.6%
30
Cancers
200 papers in training set
Top 6%
0.5%